Hyperuricemia, disease activity, and 10-year cardiovascular risk in chronic inflammatory arthritis: a post-hoc analysis of the CARMA project

OBJECTIVES: To determine the prognostic impact of hyperuricemia on cardiovascular events and its association with inflammatory markers and disease activity in patients with chronic inflammatory arthritis (CIA). METHODS: Post-hoc analysis of a 10-year prospective cohort (2010-2022) including 1,552 patients with CIA and 349 controls from 67 Spanish hospitals. Hyperuricemia was defined as serum urate (SU) >6.8 mg/dL at baseline, and its impact on major adverse cardiovascular events (MACE) during follow-up was assessed using multivariable logistic regression. Associations of hyperuricemia and SU levels with inflammatory markers and individual (swollen joint count, tender joint count, global VAS) and composite disease activity indices (DAS28, BASDAI) were analyzed using Pearson correlation and Mann-Whitney U test. RESULTS: Hyperuricemia prevalence was 11.2% in both CIA and controls, with a mean serum urate level of 5.0 ± 2.3 in the CIA group and 5.0 ± 1.4 in controls. Hyperuricemia independently increased the risk of MACE in CIA (adjusted OR 1.87, 95% CI 1.23-2.86), particularly in axial spondyloarthritis (adjusted OR 4.02, 95% CI 1.96-8.24), but not in rheumatoid arthritis or psoriatic arthritis; SU levels were not predictive. Hyperuricemia correlated with higher hsCRP levels in axial spondyloarthritis, psoriatic arthritis, and controls, but not in rheumatoid arthritis. No associations were found with ESR or disease activity indices. CONCLUSION: Baseline hyperuricemia is an independent prognostic factor for cardiovascular events in CIA, particularly in axial spondyloarthritis, but not in non-inflammatory controls. It was also associated with higher hsCRP levels, without any effect on disease activity indices. Individualized management strategies are needed in CIA.

Authors

Institutions

Publication Details

Journal
Rheumatology
Published
2026-11-12
DOI
https://doi.org/10.1093/rheumatology/keag641
Primary Topic
Gout, Hyperuricemia, Uric Acid
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hyperuricemia, disease activity, and 10-year cardiovascular risk in chronic inflammatory arthritis: a post-hoc analysis of the CARMA project

Soledad Ojeda, Mariano Andrés, S. Ros, Enrique Raya et al.
Rheumatology
Gout, Hyperuricemia, Uric Acid
article

Hyperuricemia, disease activity, and 10-year cardiovascular risk in chronic inflammatory arthritis: a post-hoc analysis of the CARMA project

Soledad Ojeda, Mariano Andrés, S. Ros, Enrique Raya, Ingrid Möller, Ana Lamuedra, Santos Castañeda, María Ángeles Belmonte-López, Miguel Ángel González-Gay, Javier Bachiller‐Corral, Horacio Berman, Pastora Granados Bautista, J. Pinto-Tasende, Ángela Pecondón, José García Torón, Martina Steiner, Isabel Rotés, Isabel Labiano, Alba Erra, Rebeca Belmonte Gómez, Alberto Cantabrana, Eugenio Chamizo Carmona, María D. Fábregas, Raimón Sanmartí, Celia Erausquin, Gloria García Consuegra, Beatriz Yoldi, Inmaculada Ros, Alfonso Corrales, Sílvia Martínez Pardo, Manuela Sianes Fernández, Fernando Sánchez‐Alonso, Ruth López‐González, Estefanía Moreno, Esmeralda Delgado, Tatiana Cañeque Cobo, Miren Uriarte-Ecenarro, Jesús Babío Herráiz, Maria J Fernandez, Ginés Sánchez Nievas, Joan Miquel Nolla Solé, Pilar Morales, Enrique Júdez Navarro, Pilar Espiño, Jesús Tornero Molina, Ramón Huguet Codina, Oscar Fontsere, María Victoria Irigoyen, Ana Ruibal Escribano, Rosario Garcia de Vicuña, Beatriz González Álvarez, Antonio Zea, Carmen Barbadillo, María Ángeles García Morales, Azucena Hernández Sanz, Javier Calvo, María Pilar Gil, Isabel Rodríguez, José Carlos Rosas, Indalecio Monteagudo, Francisco Javier López-Longo, Marta Medrano, Javier del Pino, Chesús Beltrán Audera, Eugenia Gonzalez de Rábago, Senabre Jm, Amalia Rueda, Antonio Juan, Carlos Rodríguez‐Lozano, Mónica Ibáñez, Mercedes Ramentol, Fernando Gamero, Manel Pujol, Cayetano Alegre, José L Fernández Sueiro, Benjamín Fernández Gutiérrez, Gabriela Ávila, Francisco J. Manero, Olga Martínez González, Inmaculada Ureña, Natalia Palmou, Ana Nieto, Santiago Muñoz, Alejandro Muñoz, Carmen García Gómez, Antonio Avilés Hernández, Sara Marsal, José Santos Rey, Sagrario Bustabad, for the CARMA Project Collaborative Group, Jesús A García Vadillo, Carmen O Sánchez, Antonio Fernández Nebro, Antonio J Mas, María Enriqueta Peiró, María López Lasanta, Montserrat Romera, José M Pina Salvador, José A Piqueras, Lydia Abasolo
article en

Abstract

OBJECTIVES: To determine the prognostic impact of hyperuricemia on cardiovascular events and its association with inflammatory markers and disease activity in patients with chronic inflammatory arthritis (CIA). METHODS: Post-hoc analysis of a 10-year prospective cohort (2010-2022) including 1,552 patients with CIA and 349 controls from 67 Spanish hospitals. Hyperuricemia was defined as serum urate (SU) >6.8 mg/dL at baseline, and its impact on major adverse cardiovascular events (MACE) during follow-up was assessed using multivariable logistic regression. Associations of hyperuricemia and SU levels with inflammatory markers and individual (swollen joint count, tender joint count, global VAS) and composite disease activity indices (DAS28, BASDAI) were analyzed using Pearson correlation and Mann-Whitney U test. RESULTS: Hyperuricemia prevalence was 11.2% in both CIA and controls, with a mean serum urate level of 5.0 ± 2.3 in the CIA group and 5.0 ± 1.4 in controls. Hyperuricemia independently increased the risk of MACE in CIA (adjusted OR 1.87, 95% CI 1.23-2.86), particularly in axial spondyloarthritis (adjusted OR 4.02, 95% CI 1.96-8.24), but not in rheumatoid arthritis or psoriatic arthritis; SU levels were not predictive. Hyperuricemia correlated with higher hsCRP levels in axial spondyloarthritis, psoriatic arthritis, and controls, but not in rheumatoid arthritis. No associations were found with ESR or disease activity indices. CONCLUSION: Baseline hyperuricemia is an independent prognostic factor for cardiovascular events in CIA, particularly in axial spondyloarthritis, but not in non-inflammatory controls. It was also associated with higher hsCRP levels, without any effect on disease activity indices. Individualized management strategies are needed in CIA.

Rheumatology
Universitat de Miguel Hernández d'Elx (ES), Universidad de Cantabria (ES), Bellvitge University Hospital (ES), Hospital Son Llatzer (ES), Hospital Universitario de Guadalajara (ES), University Hospital Mútua de Terrassa (ES), Hospital de Viladecans (ES), Hospital Universitario Puerta de Hierro Majadahonda (ES), Hospital Regional Universitario de Málaga (ES), Hospital Virgen de la Salud (ES), Hospital Universitario Miguel Servet (ES), Vall d'Hebron Hospital Universitari (ES), Hospital General Universitario De Valencia (ES), Hospital Virgen de la Concha (ES), Hospital Universitario Fundación Jiménez Díaz (ES), Mútua Terrassa (ES), Hospital Universitario de La Princesa (ES), Hospital General Universitario de Alicante Doctor Balmis (ES), Complexo Hospitalario Universitario A Coruña (ES), Hospital Universitario De Cabueñes (ES), Complejo Hospitalario de Cáceres (ES), Hospital Universitario Ramón y Cajal (ES), Hospital Universitario Infanta Leonor (ES), Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL) (ES), Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa (ES), Instituto de Investigación Sanitaria Fundación Jiménez Díaz (ES)
Gout, Hyperuricemia, Uric Acid
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon